A large postmortem study has narrowed where TDP-43 pathology appears in the motor cortex of people with amyotrophic lateral sclerosis and combined ALS-frontotemporal dementia. The researchers identified five neuronal cell types that were especially associated with the abnormal loss of TDP-43 from the nucleus.
The Nature Communications study used single-nucleus RNA sequencing, chromatin-accessibility data, spatial mapping and direct sorting of nuclei with low or preserved TDP-43. It offers a more precise cell map of disease pathology. It did not test a drug, an early diagnostic test or an intervention in living patients.
ALS primarily damages motor function, while frontotemporal dementia can affect behaviour, language and cognition. Their clinical and biological overlap is well established, and TDP-43 pathology is common across the spectrum.
The Study Used Donated Brain Tissue
The research included 82 postmortem samples across two datasets. The larger multi-omic dataset contained tissue from 30 people with ALS, 10 with ALS-FTD and 32 age- and sex-matched controls without neuropathology. A second dataset enriched neuronal nuclei according to their TDP-43 signal.
Postmortem tissue allows researchers to measure pathology directly at cellular resolution. It also captures disease after it has developed and cannot establish the exact sequence of changes during a person's life. The authors noted incomplete clinical data and limits in separating ALS and ALS-FTD phenotypes.
The analysis focused on the motor cortex. Some rare cell types were represented by relatively few nuclei, including roughly 500 cells identified as Betz-cell candidates. The authors said future studies would need to enrich these cells for deeper analysis.
Five Neuron Types Showed Greater Vulnerability
The team found that TDP-43 pathology was not distributed evenly. Specific excitatory and inhibitory neuron types were enriched among nuclei with strongly reduced nuclear TDP-43. This included intratelencephalic neurons in layers 2-3 and layer 6 as well as selected interneuron populations.
TDP-43 normally helps regulate RNA inside the nucleus. In ALS and many ALS-FTD cases, it can leave the nucleus and form abnormal aggregates in the cell body. The study used reduced nuclear TDP-43 as a direct marker and then measured the molecular changes associated with affected cell types.
Those changes differed by cell type and were not identical to the broader gene-expression differences seen when all ALS or ALS-FTD tissue was compared with control tissue. That distinction suggests that disease-wide inflammation or tissue change and cell-specific TDP-43 pathology should not be treated as the same signal.
The Findings Refine a Mechanism, Not a Cure
The study found changes in gene activity and chromatin accessibility, including pathways related to axon guidance. Such results can help researchers choose mechanisms for further experiments. They do not show that altering one gene or pathway will protect neurons in people.
DZNE researcher Karin Danzer said the unequal vulnerability suggests that future therapies may need to be tailored to specific cell types. That is a research implication, not evidence that a cell-targeted treatment is available or that delivery to the relevant cortex has been solved.
The data also do not support a simple story in which large neurons fail because they use more energy or lack a particular protective chaperone. Those mechanisms were not established by this study. Nor did the work demonstrate a predictable anatomical spread from Betz cells to spinal motor neurons.
A Better Map Still Needs Prospective Evidence
The map can improve experimental design by telling researchers which cells to enrich, model and compare. Replication in additional brain banks, longitudinal models and samples representing different genetic and clinical forms will be needed to determine how general the pattern is.
It is also too early to turn the result into patient selection. A postmortem molecular signature cannot by itself identify which living patient will progress quickly, develop cognitive symptoms or respond to a future therapy. Biomarkers usable during life would require separate validation.
The study's value is precision: it replaces the vague statement that neurons are vulnerable with testable cell identities and molecular signatures. Its limit is equally precise. Mapping where pathology accumulated does not prove why it began or how to stop it. Funding arguments and promises of targeted delivery do not close that gap; experiments that connect these cell signatures to disease timing, safety and treatment response do.